4//SEC Filing
Ueno Ryuji 4
Accession 0000899243-18-003892
CIK 0001365216other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 5:47 PM ET
Size
8.6 KB
Accession
0000899243-18-003892
Insider Transaction Report
Form 4
Ueno Ryuji
DirectorCEO, Chief Scientific Officer10% Owner
Transactions
- Gift
Class A Common Stock
2017-12-19−600,000→ 7,406,585 total(indirect: By LLC) - Gift
Class A Common Stock
2018-01-29−2,000,000→ 5,406,585 total(indirect: By LLC) - Disposition from Tender
Class A Common Stock
2018-02-13$18.00/sh−5,406,585$97,318,530→ 0 total(indirect: By LLC)
Footnotes (1)
- [F1]Disposed of upon expiration of the tender offer conducted by Sun Acquisition Co., a Delaware corporation ("Purchaser"), pursuant to the terms of the Agreement and Plan of Merger, dated as of December 26, 2017, among Sucampo Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), Mallinckrodt plc, an Irish public limited company ("Parent"), and Purchaser, a wholly owned subsidiary of Parent, whereby Purchaser offered to purchase each outstanding share of Class A Common Stock, par value $0.01 per share, of the Issuer at a purchase price of $18.00 per share in cash, subject to any required withholding of taxes and without interest.
Documents
Issuer
Sucampo Pharmaceuticals, Inc.
CIK 0001365216
Entity typeother
Related Parties
1- filerCIK 0001384370
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 5:47 PM ET
- Size
- 8.6 KB